BACKGROUND: The safety of fibrin tissue adhesives has been a concern since they entered wide clinical application. Most commercially available kits contain the proteolytic inhibitor, aprotinin, to stabilize the fibrin clot. A bovine protein, this substance has an allergenic potency. CASE REPORT: This case report presents a patient who had a generalized allergic skin reaction, probably triggered by aprotinin upon reexposure to fibrin sealant injected subgaleally to achieve closure of a liquor fistula after neurosurgical treatment. The serologic investigation revealed aprotinin-specific IgE and IgG. From 1990 through 1998, reports of five allergic reactions following 1 million exposures to fibrin sealant were made to the manufacturer. The clinical relevance of allergic reactions to aprotinin contained in fibrin sealants and measures to avoid them are discussed. CONCLUSION: These hypersensitivity reactions are extremely rare (incidence, 0.5/100,000 for all reactions and 0.3/100,000 for serious reactions), but they must be kept in mind as possible adverse events after repeated applications of fibrin sealants within a few weeks.
BACKGROUND: The safety of fibrin tissue adhesives has been a concern since they entered wide clinical application. Most commercially available kits contain the proteolytic inhibitor, aprotinin, to stabilize the fibrin clot. A bovine protein, this substance has an allergenic potency. CASE REPORT: This case report presents a patient who had a generalized allergic skin reaction, probably triggered by aprotinin upon reexposure to fibrin sealant injected subgaleally to achieve closure of a liquor fistula after neurosurgical treatment. The serologic investigation revealed aprotinin-specific IgE and IgG. From 1990 through 1998, reports of five allergic reactions following 1 million exposures to fibrin sealant were made to the manufacturer. The clinical relevance of allergic reactions to aprotinin contained in fibrin sealants and measures to avoid them are discussed. CONCLUSION: These hypersensitivity reactions are extremely rare (incidence, 0.5/100,000 for all reactions and 0.3/100,000 for serious reactions), but they must be kept in mind as possible adverse events after repeated applications of fibrin sealants within a few weeks.
Authors: Christine L Weisshaar; Jessamine P Winer; Benjamin B Guarino; Paul A Janmey; Beth A Winkelstein Journal: Biomaterials Date: 2011-09-22 Impact factor: 12.479
Authors: Ahmed Diab; Hieder Al-Shami; Ahmed Negida; Ahmed Gadallah; Hossam Farag; Doaa Mahmoud Elkadi; Mo'tasem Muhamed Gaber; Mahmoud Ahmed Ebada Journal: Surg Neurol Int Date: 2021-04-26
Authors: Justus P Beier; Dorothee Klumpp; Markus Rudisile; Roland Dersch; Joachim H Wendorff; Oliver Bleiziffer; Andreas Arkudas; Elias Polykandriotis; Raymund E Horch; Ulrich Kneser Journal: BMC Biotechnol Date: 2009-04-15 Impact factor: 2.563
Authors: Felice Esposito; Filippo Flavio Angileri; Peter Kruse; Luigi Maria Cavallo; Domenico Solari; Vincenzo Esposito; Francesco Tomasello; Paolo Cappabianca Journal: PLoS One Date: 2016-04-27 Impact factor: 3.240